scholarly journals Corrigendum to “Targeting V-ATPase Isoform Restores Cisplatin Activity in Resistant Ovarian Cancer: Inhibition of Autophagy, Endosome Function, and ERK/MEK Pathway”

2021 ◽  
Vol 2021 ◽  
pp. 1-2
Author(s):  
Arpita Kulshrestha ◽  
Gajendra K. Katara ◽  
Safaa A. Ibrahim ◽  
Valerie Riehl ◽  
Manoranjan Sahoo ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Inhibition

scholarly journals Rucaparib: a PARP inhibitor for the treatment of advanced ovarian cancer

2017 ◽  
Vol 6 (4) ◽  
pp. 1018 ◽  
Author(s):  
Merin Babu ◽  
Josini C. J.
Keyword(s):  
Ovarian Cancer ◽  
Brca Mutation ◽  
Parp Inhibitor ◽  
Advanced Ovarian Cancer ◽  
Chemotherapeutic Agents ◽  
The Us ◽  
The Common ◽  
Us Fda ◽  
Novel Drug ◽  
Cancer Inhibition

Ovarian cancers arise from the uncontrolled growth and replication of epithelial cells of the surface of ovary which constitutes 90% of cases. PARP (poly ADP-ribose polymerase) inhibitors are a novel type of therapy that prevents cancer cells from repairing their DNA which have been damaged by other chemotherapeutic agents. Rucaparib is a novel drug that was approved by the US FDA in 2016 for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer. Inhibition of the PARP enzymes leads to the increased formation of PARP-DNA complexes which results in DNA damage, apoptosis and cell death. Nausea, fatigue including asthenia, vomiting, anemia, abdominal pain, constipation, decreased appetite, diarrhea, thrombocytopenia and dyspnea were the common adverse effects seen among rucaparib users. Even though, the drug may cause myleodysplastic syndrome/ acute myeloid leukemia (MDS/AML) it remains as novel therapeutic target for the treatment of advanced ovarian cancer involving BRCA mutation.

scholarly journals Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System

2018 ◽  
Vol 19 (1) ◽  
pp. 273 ◽  
Author(s):  
Christina Wefers ◽  
Tjitske Duiveman-de Boer ◽  
Petra Zusterzeel ◽  
Leon Massuger ◽  
David Fuchs ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Cancer Inhibition ◽  
Lipid Regulation

Impact of extended cycles of chemotherapy on survival outcome in recurrent epithelial ovarian cancer

2020 ◽  
Vol 159 ◽  
pp. 346-347
Author(s):  
W.Y. Hwang ◽  
S.I. Kim ◽  
M. Lee ◽  
K. Kim ◽  
J.H. No ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Survival Outcome
Sign in / Sign up

Export Citation Format

Share Document